This ETF is trying to satisfy appetites for weight loss stocks
Tema ETFs is behind the GLP-1, Obesity & Cardiometabolic ETF (HRTS), which is up 26% since its inception last November.
Read MoreTema ETFs is behind the GLP-1, Obesity & Cardiometabolic ETF (HRTS), which is up 26% since its inception last November.
Read MoreThe results are a sign that Altimmune can address an area of concern around weight loss drugs, which is that
Read MoreSome health plans and employers are still reluctant to cover Wegovy due to its hefty price tag, which they say
Read MoreNovo Nordisk and Eli Lilly have given positive supply updates, aiming to reassure investors that they can continue to capitalize
Read MoreLillyDirect is the latest attempt to simplify what critics call a complex system for distributing, pricing and prescribing prescription drugs.
Read More2024 will be another big year for weight loss drugs, which soared in popularity despite hefty price tags, mixed insurance
Read MorePfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug,
Read MoreTwo experts see major challenges facing the adoption of Novo Nordisk and Eli Lilly's obesity drugs. Source link
Read MoreThe data confirms the rise in demand for GLP-1s, which have fueled a frenzy among Americans and on Wall Street
Read More